The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas

被引：38

作者：

Liu, Xiaoshuang ^{[1
,2
]}

Tang, Chao ^{[3
]}

Wen, Guodao ^{[4
]}

Zhong, Chunyu ^{[5
]}

Yang, Jin ^{[5
]}

Zhu, Junhao ^{[5
]}

Ma, Chiyuan ^{[3
]}

机构：

[1] Nanjing Univ, NJU Adv Inst Life Sci, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China

[2] Nanjing Univ, NJU Adv Inst Life Sci, Sch Life Sci, Jiangsu Engn Res Ctr MicroRNA Biol & Biotechnol, Nanjing, Jiangsu, Peoples R China

[3] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China

[4] Sun Yat Sen Univ, Tungwah Hosp, Dongguan, Peoples R China

[5] Nanjing Med Univ, Sch Med, Nanjing, Jiangsu, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2019年 / 9卷

关键词：

dopamine agonists; bromocriptine; cabergoline; programmed cell death; prolactinomas; BROMOCRIPTINE-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; DEPENDENT CELL-DEATH; D2; RECEPTORS; PITUITARY-CELLS; ISOFORMS; RESISTANT; AUTOPHAGY; EXPRESSION; DIAGNOSIS;

D O I：

10.3389/fendo.2018.00768

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.

引用

页数：6

共 50 条

[1] PROLACTINOMAS AND RESISTANCE TO DOPAMINE AGONISTS
BRUE, T
PELLEGRINI, I
PRIOU, A
MORANGE, I
JAQUET, P
HORMONE RESEARCH, 1992, 38 (1-2) : 84 - 89
[2] Experience with Dopamine Agonists in the Treatment of Prolactinomas
Barabash, Nadiya Ye.
Tykhonova, Tetiana M.
ACTA MEDICA LITUANICA, 2022, 29 (02) : 311 - 317
[3] Dopamine agonists in prolactinomas: when to withdraw?
Pedro Souteiro
Sandra Belo
Davide Carvalho
Pituitary, 2020, 23 : 38 - 44
[4] Dopamine receptor agonists for treating prolactinomas
Colao, A
di Sarno, A
Pivonello, R
di Somma, C
Lombardi, G
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 787 - 800
[5] Dopamine agonists in prolactinomas: when to withdraw?
Souteiro, Pedro
Belo, Sandra
Carvalho, Davide
PITUITARY, 2020, 23 (01) : 38 - 44
[6] Hypersexuality in men with prolactinomas treated with dopamine agonists
Bancos, Irina
Nippoldt, Todd B.
Erickson, Dana
ENDOCRINE, 2017, 56 (03) : 456 - 457
[7] Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment
Shimon, Ilan
ARCHIVES OF MEDICAL RESEARCH, 2023, 54 (08)
[8] Dopamine Agonists Can Reduce Cystic Prolactinomas
Faje, Alexander
Chunharojrith, Paweena
Nency, Joshipura
Biller, Beverly M. K.
Swearingen, Brooke
Klibanski, Anne
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (10): : 3709 - 3715
[9] Hypersexuality in men with prolactinomas treated with dopamine agonists
Irina Bancos
Todd B. Nippoldt
Dana Erickson
Endocrine, 2017, 56 : 456 - 457
[10] Prolactinomas, dopamine agonists and headache: two case reports
Levy, MJ
Matharu, MS
Goadsby, PJ
EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (02) : 169 - 173

← 1 2 3 4 5 →